Want to see FR:ALMIB full AI Analyst Report?
ALMIB Stock Chart & Stats
€0.68
<€0.01(0.15%)
At close: 4:00 PM EDT
€0.68
<€0.01(0.15%)
Day’s Range― - ―
52-Week Range€0.30 - €1.20
Previous CloseN/A
Volume48.65K
Average Volume (3M)809.05K
Market Cap
€32.15M
Enterprise Value€78.49
Total Cash (Recent Filing)€4.72M
Total Debt (Recent Filing)€12.24M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding96,884,340
10 Day Avg. Volume1,900,917
30 Day Avg. Volume809,049
Financial Highlights & Ratios
PEG Ratio1.15
Price to Book (P/B)-13.62
Price to Sales (P/S)0.00
P/FCF Ratio-9.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€4.05M
Bulls Say, Bears Say
Bulls Say
Biological Agriculture PlatformAmoéba has a defined biological platform serving agriculture, with biocontrol and biofertilizer applications. This positions the company within the longer-term shift toward biological crop inputs, while the shared platform could support multiple products and market opportunities if commercialization progresses.
Losses Narrowed In 2025The reduction in operating losses compared with 2023 indicates some progress in cost or operating performance, even though profitability remains deeply negative. If maintained, further loss reduction could extend financial runway and improve the prospects for eventual operating leverage.
Free Cash Flow Improved Versus 2024Free cash flow remained negative, but the improvement from 2024 shows that cash consumption was moving in a less adverse direction at the latest annual report. Continued improvement would reduce funding pressure and make future commercialization investment more manageable.
Bears Say
Revenue Collapsed To ZeroThe collapse to effectively zero revenue demonstrates that the business has not yet established dependable commercial scale. Without recurring sales growth, fixed research, development, and operating costs remain difficult to absorb, limiting the credibility of near-term margin improvement.
Persistent Deep LossesRecurring net losses across the reported years show that the company has not reached sustainable profitability. This weak earnings base can constrain reinvestment, increase dependence on financing, and make execution of product development and commercialization plans more financially demanding.
Negative Equity And Higher DebtNegative equity combined with materially higher debt indicates a weakened capital structure and limited financial flexibility. The greater leverage raises refinancing risk and leaves less capacity to absorb setbacks or fund growth internally, increasing reliance on external capital.
Amoeba SA News
ALMIB FAQ
What was Amoeba SA’s price range in the past 12 months?
Amoeba SA lowest stock price was €0.30 and its highest was €1.20 in the past 12 months.
What is Amoeba SA’s market cap?
Amoeba SA’s market cap is €32.15M.
When is Amoeba SA’s upcoming earnings report date?
Amoeba SA’s upcoming earnings report date is Apr 01, 2027 which is in 182 days.
How were Amoeba SA’s earnings last quarter?
Amoeba SA released its earnings results on Sep 24, 2026. The company reported -€0.095 earnings per share for the quarter.
Is Amoeba SA overvalued?
According to Wall Street analysts Amoeba SA’s price is currently Overvalued.
Does Amoeba SA pay dividends?
Amoeba SA does not currently pay dividends.
What is Amoeba SA’s EPS estimate?
Amoeba SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amoeba SA have?
Amoeba SA has 96,884,340 shares outstanding.
What happened to Amoeba SA’s price movement after its last earnings report?
Amoeba SA reported an EPS of -€0.095 in its last earnings report. Following the earnings report the stock price went down -3.421%.
Which hedge fund is a major shareholder of Amoeba SA?
Currently, no hedge funds are holding shares in FR:ALMIB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Amoeba SA
Amoéba S.A. focuses on the development and commercialization of anti-microbial and anti-fungal products. The company's primary innovation centers on harnessing the unique properties of the Willaertia magna C2c Maky amoeba, which it is applying across various fields. These applications are designed to mitigate biological risks in critical areas like water purification, the treatment of human injuries, and safeguarding agricultural crops. Established in 2010, Amoéba S.A. is based in Chassieu, France.